WO2006105359A3 - Methods for stimulating hair growth by administering bmps - Google Patents
Methods for stimulating hair growth by administering bmps Download PDFInfo
- Publication number
- WO2006105359A3 WO2006105359A3 PCT/US2006/011799 US2006011799W WO2006105359A3 WO 2006105359 A3 WO2006105359 A3 WO 2006105359A3 US 2006011799 W US2006011799 W US 2006011799W WO 2006105359 A3 WO2006105359 A3 WO 2006105359A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- methods
- bmps
- administering
- hair growth
- stimulating hair
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Abstract
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06740137A EP1863518A2 (en) | 2005-03-30 | 2006-03-30 | Methods for stimulating hair growth by administering bmps |
CA002601436A CA2601436A1 (en) | 2005-03-30 | 2006-03-30 | Methods for stimulating hair growth by administering bmps |
JP2008504403A JP2008534607A (en) | 2005-03-30 | 2006-03-30 | Method for stimulating hair growth by administering BMP |
BRPI0609504-6A BRPI0609504A2 (en) | 2005-03-30 | 2006-03-30 | methods to stimulate hair growth by administering bone morphogenetic proteins (bmps) |
AU2006230434A AU2006230434A1 (en) | 2005-03-30 | 2006-03-30 | Methods for stimulating hair growth by administering BMPs |
MX2007011591A MX2007011591A (en) | 2005-03-30 | 2006-03-30 | Methods for stimulating hair growth by administering bmps. |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US66617205P | 2005-03-30 | 2005-03-30 | |
US60/666,172 | 2005-03-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2006105359A2 WO2006105359A2 (en) | 2006-10-05 |
WO2006105359A3 true WO2006105359A3 (en) | 2006-12-07 |
Family
ID=36648737
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2006/011799 WO2006105359A2 (en) | 2005-03-30 | 2006-03-30 | Methods for stimulating hair growth by administering bmps |
Country Status (9)
Country | Link |
---|---|
US (1) | US20060239951A1 (en) |
EP (1) | EP1863518A2 (en) |
JP (1) | JP2008534607A (en) |
CN (1) | CN101309698A (en) |
AU (1) | AU2006230434A1 (en) |
BR (1) | BRPI0609504A2 (en) |
CA (1) | CA2601436A1 (en) |
MX (1) | MX2007011591A (en) |
WO (1) | WO2006105359A2 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100047299A1 (en) * | 2007-01-25 | 2010-02-25 | Biopharm Gesellschaft Zur Biotechnologischen Entwicklung Von Pharmaka Mbh | Use of gdf-5 for the improvement or maintenance of dermal appearance |
CN101301467B (en) * | 2008-04-22 | 2012-01-25 | 同济大学 | Uses of BMP-7 in preparing medicament for preventing and/or treating liver fibrosis |
IT1392903B1 (en) * | 2008-07-29 | 2012-04-02 | Marino Salin | COMPOSITION INCLUDING AN ASSOCIATION OF ACTIVE PRINCIPLES FOR USE IN THE TOPIC TREATMENT OF CALVIZIE |
WO2010029343A2 (en) * | 2008-09-10 | 2010-03-18 | University Of Bradford | Compositions and methods |
PT2344198T (en) * | 2008-09-27 | 2020-12-04 | Jina Pharmaceuticals Inc | Lipid based pharmaceutical preparations for oral and topical application; their compositions, methods, and uses thereof |
EP3693014A1 (en) * | 2008-11-13 | 2020-08-12 | The General Hospital Corporation | Methods and compositions for regulating iron homeostasis by modulation bmp-6 |
WO2010059861A1 (en) * | 2008-11-20 | 2010-05-27 | University Of Southern California | Compositions and methods to modulate hair growth |
KR101355809B1 (en) | 2012-03-13 | 2014-01-28 | 우리들생명과학 주식회사 | Composition for inducing a bone differentiation and method for enhancing a bone differentiation using the same |
US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
US9445980B2 (en) * | 2012-04-18 | 2016-09-20 | Mark Laney | Methods for stimulating hair growth |
WO2014052393A2 (en) | 2012-09-25 | 2014-04-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods for the diagnosis and treatment of sjögren's syndrome |
CN112933223A (en) * | 2012-10-24 | 2021-06-11 | 细胞基因公司 | Methods for treating anemia |
US20140315803A1 (en) * | 2013-04-17 | 2014-10-23 | Mark Laney | Methods for stimulating hair growth |
KR20150000242A (en) * | 2013-06-24 | 2015-01-02 | 고려대학교 산학협력단 | Compositions Containing BMP6 for Preventing or Treating Psoriasis and Health Foods Containing BMP6 for Preventing or Improving Psoriasis |
US9937117B2 (en) * | 2015-07-09 | 2018-04-10 | Galderma S.A. | Method of reducing hair loss associated with chemotherapy |
CN108129572B (en) * | 2018-01-04 | 2021-01-29 | 河南大学 | Application of human GDF11-Fc fusion protein in treating ulcerative colitis |
CN110237237A (en) * | 2019-06-10 | 2019-09-17 | 上海交通大学医学院附属上海儿童医学中心 | Application of the BMP4 albumen as preparation treatment autoimmune disease drug |
CN110638833A (en) * | 2019-11-15 | 2020-01-03 | 西安圣德生物科技有限公司 | Composition for promoting hair growth and method of use thereof |
US20210315834A1 (en) * | 2020-04-12 | 2021-10-14 | Sol-Gel Technologies Ltd. | Treatment of alopecia |
KR102553476B1 (en) * | 2020-10-30 | 2023-07-11 | (의료)길의료재단 | Pharmaceutical composition for preventing or treating metabolic diseases comprising bone morphogenetic protein 10 |
CN114699506A (en) * | 2021-12-30 | 2022-07-05 | 北京百华百汇生物科技有限公司 | Use of recombinant calreticulin for growing hair, protecting hair or preventing alopecia and related products |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005002068A (en) * | 2003-06-13 | 2005-01-06 | Lion Corp | Method for growing and restoring hair, hair growing and restoring agent and method for screening hair growing and restoring agent |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5215893A (en) * | 1985-10-03 | 1993-06-01 | Genentech, Inc. | Nucleic acid encoding the ba chain prodomains of inhibin and method for synthesizing polypeptides using such nucleic acid |
US6432919B1 (en) * | 1986-07-01 | 2002-08-13 | Genetics Institute, Inc. | Bone morphogenetic protein-3 and compositions |
US5459047A (en) * | 1986-07-01 | 1995-10-17 | Genetics Institute, Inc. | BMP-6 proteins |
US5631142A (en) * | 1986-07-01 | 1997-05-20 | Genetics Institute, Inc. | Compositions comprising bone morphogenetic protein-2 (BMP-2) |
US6150328A (en) * | 1986-07-01 | 2000-11-21 | Genetics Institute, Inc. | BMP products |
US5939388A (en) * | 1986-07-01 | 1999-08-17 | Rosen; Vicki A. | Methods of administering BMP-5 compositions |
US5013649A (en) * | 1986-07-01 | 1991-05-07 | Genetics Institute, Inc. | DNA sequences encoding osteoinductive products |
US5543394A (en) * | 1986-07-01 | 1996-08-06 | Genetics Institute, Inc. | Bone morphogenetic protein 5(BMP-5) compositions |
US5457092A (en) * | 1987-07-30 | 1995-10-10 | Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) | Methods of promoting bone growth in mammals comprising administration of modified parathyroid hormone |
US6586388B2 (en) * | 1988-04-08 | 2003-07-01 | Stryker Corporation | Method of using recombinant osteogenic protein to repair bone or cartilage defects |
US5258494A (en) * | 1988-04-08 | 1993-11-02 | Stryker Corporation | Osteogenic proteins |
US5354557A (en) * | 1988-04-08 | 1994-10-11 | Stryker Corporation | Osteogenic devices |
US5266683A (en) * | 1988-04-08 | 1993-11-30 | Stryker Corporation | Osteogenic proteins |
US5284756A (en) * | 1988-10-11 | 1994-02-08 | Lynn Grinna | Heterodimeric osteogenic factor |
US5457038A (en) * | 1988-11-10 | 1995-10-10 | Genetics Institute, Inc. | Natural killer stimulatory factor |
US5162430A (en) * | 1988-11-21 | 1992-11-10 | Collagen Corporation | Collagen-polymer conjugates |
US5217867A (en) * | 1988-11-30 | 1993-06-08 | The Salk Institute For Biological Studies | Receptors: their identification, characterization, preparation and use |
WO1990010067A1 (en) * | 1989-02-23 | 1990-09-07 | GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) | Dna sequences coding for pth variants, pth variants, expression vector, bacterial host, use and therapeutic composition |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
WO1991000103A1 (en) * | 1989-06-29 | 1991-01-10 | The United States Of America, Represented By The Secretary, United States Department Of Commerce | Method for protecting bone marrow against chemotherapeutic drugs and radiation therapy using transforming growth factor beta 1 |
US5324519A (en) * | 1989-07-24 | 1994-06-28 | Atrix Laboratories, Inc. | Biodegradable polymer composition |
US5422340A (en) * | 1989-09-01 | 1995-06-06 | Ammann; Arthur J. | TGF-βformulation for inducing bone growth |
US5236456A (en) * | 1989-11-09 | 1993-08-17 | Osteotech, Inc. | Osteogenic composition and implant containing same |
GB8927546D0 (en) * | 1989-12-06 | 1990-02-07 | Ciba Geigy | Process for the production of biologically active tgf-beta |
US5290271A (en) * | 1990-05-14 | 1994-03-01 | Jernberg Gary R | Surgical implant and method for controlled release of chemotherapeutic agents |
US5218090A (en) * | 1990-06-12 | 1993-06-08 | Warner-Lambert Company | EGF receptor truncates |
US5364839A (en) * | 1990-06-18 | 1994-11-15 | Genetics Institute, Inc. | Osteoinductive pharmaceutical formulations |
US5206028A (en) * | 1991-02-11 | 1993-04-27 | Li Shu Tung | Dense collagen membrane matrices for medical uses |
US5208219A (en) * | 1991-02-14 | 1993-05-04 | Celtrix Pharmaceuticals Inc. | Method for inducing bone growth |
US5318898A (en) * | 1991-04-02 | 1994-06-07 | Genetics Institute, Inc. | Production of recombinant bone-inducing proteins |
US5229495A (en) * | 1991-06-18 | 1993-07-20 | Ludwig Institute For Cancer Research | Substantially pure receptor like TGF-β 1 binding molecules and uses thereof |
US5216126A (en) * | 1991-06-19 | 1993-06-01 | Genentech, Inc. | Receptor polypeptides and their production and uses |
US6287816B1 (en) * | 1991-06-25 | 2001-09-11 | Genetics Institute, Inc. | BMP-9 compositions |
DK0592562T3 (en) * | 1991-06-25 | 1999-08-30 | Genetics Inst | BMP-9 compositions |
US5356629A (en) * | 1991-07-12 | 1994-10-18 | United States Surgical Corporation | Composition for effecting bone repair |
US5306307A (en) * | 1991-07-22 | 1994-04-26 | Calcitek, Inc. | Spinal disk implant |
JP3504263B2 (en) * | 1991-11-04 | 2004-03-08 | ジェネティックス・インスチチュート・リミテッド・ライアビリティ・カンパニー | Recombinant bone morphogenetic protein heterodimers, compositions and uses |
ATE208217T1 (en) * | 1992-02-28 | 2001-11-15 | Cohesion Tech Inc | INJECTABLE CERAMIC COMPOUNDS AND METHOD FOR THEIR PRODUCTION AND USE |
AU3920693A (en) * | 1992-03-18 | 1993-10-21 | General Hospital Corporation, The | Four novel receptors of the TGF-beta receptor family |
IT1259100B (en) * | 1992-05-20 | 1996-03-11 | Lanfranco Callegaro | USE OF HYDROGELS FOR THE LOCKING OF PROSTHETIC SYSTEMS |
US5420243A (en) * | 1993-01-26 | 1995-05-30 | Celtrix Pharmaceuticals, Inc. | Biologically active TGF-β2 peptides |
DE69432815T2 (en) * | 1993-03-19 | 2003-12-11 | Univ Johns Hopkins Med | GROWTH FACTOR-8 |
GB9308060D0 (en) * | 1993-04-19 | 1993-06-02 | Cancer Res Campaign Tech | Stem cell inhibitor |
US5637480A (en) * | 1993-05-12 | 1997-06-10 | Genetics Institute, Inc. | DNA molecules encoding bone morphogenetic protein-10 |
DE69433530T2 (en) * | 1993-05-12 | 2005-01-05 | Genetics Institute, LLC, Cambridge | BMP-11 COMPOSITIONS |
US5447725A (en) * | 1993-06-11 | 1995-09-05 | The Procter & Gamble Company | Methods for aiding periodontal tissue regeneration |
ATE326234T1 (en) * | 1993-08-26 | 2006-06-15 | Genetics Inst Llc | HUMAN BONE MORPHOGENETIC PROTEINS FOR USE IN NEURONAL REGENERATION |
US5455041A (en) * | 1993-09-13 | 1995-10-03 | Research Foundation Of State University Of New York At Buffalo | Method for inducing periodontal tissue regeneration |
US6291206B1 (en) * | 1993-09-17 | 2001-09-18 | Genetics Institute, Inc. | BMP receptor proteins |
AU8095694A (en) * | 1993-10-28 | 1995-05-22 | Thm Biomedical, Inc. | Improved process and device for treating and healing a bone void |
US5399677A (en) * | 1993-12-07 | 1995-03-21 | Genetics Institute, Inc. | Mutants of bone morphogenetic proteins |
ES2255059T3 (en) * | 1993-12-07 | 2006-06-16 | Genetics Institute, Llc | BMP-12, BMP-13 AND YOUR INDUCTION COMPOSITIONS OF TENDON. |
US6027919A (en) * | 1993-12-07 | 2000-02-22 | Genetics Institute, Inc. | BMP-12 and BMP-13 proteins and DNA encoding them |
US5556767A (en) * | 1993-12-22 | 1996-09-17 | Human Genome Sciences, Inc. | Polynucleotide encoding macrophage inflammatory protein γ |
US5723331A (en) * | 1994-05-05 | 1998-03-03 | Genzyme Corporation | Methods and compositions for the repair of articular cartilage defects in mammals |
US5520923A (en) * | 1994-09-19 | 1996-05-28 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
US5545616A (en) * | 1994-09-22 | 1996-08-13 | Genentech, Inc. | Method for predicting and/or preventing preterm labor |
US5635372A (en) * | 1995-05-18 | 1997-06-03 | Genetics Institute, Inc. | BMP-15 compositions |
AU699918B2 (en) * | 1995-06-05 | 1998-12-17 | Genetics Institute, Llc | Methods and compositions for healing and repair of connective tissue attachment |
US5674292A (en) * | 1995-06-07 | 1997-10-07 | Stryker Corporation | Terminally sterilized osteogenic devices and preparation thereof |
JP3521164B2 (en) * | 1995-10-02 | 2004-04-19 | ヤマハ発動機株式会社 | Exhaust system for motorcycle |
JP2000501966A (en) * | 1995-12-18 | 2000-02-22 | デグッサ アクチエンゲゼルシャフト | Medical implant |
CA2256400A1 (en) * | 1996-05-28 | 1997-12-04 | Brown University Research Foundation | Hyaluronan based biodegradable scaffolds for tissue repair |
US5813411A (en) * | 1996-08-20 | 1998-09-29 | Menlo Care, Inc. | Method of deforming tissue with a swollen hydrogel |
US5965403A (en) * | 1996-09-18 | 1999-10-12 | Genetics Institute, Inc. | Nucleic acids encoding bone morphogenic protein-16 (BMP-16) |
BR9713348A (en) * | 1996-11-12 | 2000-08-08 | Dov Tamarkin | Method for treating dermatological disorders |
US6034062A (en) * | 1997-03-13 | 2000-03-07 | Genetics Institute, Inc. | Bone morphogenetic protein (BMP)-9 compositions and their uses |
US5972368A (en) * | 1997-06-11 | 1999-10-26 | Sdgi Holdings, Inc. | Bone graft composites and spacers |
IT1302534B1 (en) * | 1998-12-21 | 2000-09-05 | Fidia Advanced Biopolymers Srl | INJECTABLE, BIOCOMPATIBLE AND BIODEGRADABLE COMPOSITIONS INCLUDING AT LEAST A DERIVATIVE OF HYALURONIC ACID, CHONDROGENIC CELLS, FOR |
KR100748297B1 (en) * | 2000-02-29 | 2007-08-09 | 알콘, 인코퍼레이티드 | Diagnostics and therapeutics for glaucoma |
JP2004525930A (en) * | 2001-03-23 | 2004-08-26 | バイオファーム・ゲゼルシャフト・ツア・バイオテクノロジシェン・エントヴィックルング・フォン・ファーマカ・ミット・ベシュレンクテル・ハフツング | Use of TGF-β superfamily cytokines for the treatment and diagnosis of skin related diseases |
ATE393573T1 (en) * | 2001-06-01 | 2008-05-15 | Wyeth Corp | COMPOSITIONS FOR SYSTEMIC ADMINISTRATION OF SEQUENCES ENCODING BONE MORPHOGENESIS PROTEINS |
-
2006
- 2006-03-30 EP EP06740137A patent/EP1863518A2/en not_active Withdrawn
- 2006-03-30 CN CNA200680010142XA patent/CN101309698A/en active Pending
- 2006-03-30 AU AU2006230434A patent/AU2006230434A1/en not_active Abandoned
- 2006-03-30 WO PCT/US2006/011799 patent/WO2006105359A2/en active Application Filing
- 2006-03-30 JP JP2008504403A patent/JP2008534607A/en active Pending
- 2006-03-30 BR BRPI0609504-6A patent/BRPI0609504A2/en not_active Application Discontinuation
- 2006-03-30 MX MX2007011591A patent/MX2007011591A/en not_active Application Discontinuation
- 2006-03-30 US US11/393,498 patent/US20060239951A1/en not_active Abandoned
- 2006-03-30 CA CA002601436A patent/CA2601436A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005002068A (en) * | 2003-06-13 | 2005-01-06 | Lion Corp | Method for growing and restoring hair, hair growing and restoring agent and method for screening hair growing and restoring agent |
Non-Patent Citations (6)
Title |
---|
ANNALI ITALIANI DI DERMATOLOGIA CLINICA E SPERIMENTALE, vol. 41, no. 4, 1987, pages 383 - 391, ISSN: 0365-169X * |
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1987, SBANO E ET AL: "MINOXIDIL-CYCLOSPORIN A ASSOCIATION IN THE TREATMENT OF ALOPECIA UNIVERSALIS CLINICAL AND IMMUNOLOGICAL OBSERVATIONS", XP002391212, Database accession no. PREV198886062188 * |
DATABASE WPI Section Ch Week 200507, Derwent World Patents Index; Class B04, AN 2005-061576, XP002390695 * |
LESLIE K S ET AL: "Alopecia universalis treated with bone morphogenetic protein?", BRITISH JOURNAL OF DERMATOLOGY, vol. 154, no. 1, January 2006 (2006-01-01), pages 190 - 191, XP002390573, ISSN: 0007-0963 * |
MIDORIKAWA T ET AL: "Different gene expression profile observed in dermal papilla cells related to androgenic alopecia by DNA macroarray analysis", JOURNAL OF DERMATOLOGICAL SCIENCE, ELSEVIER SCIENCE PUBLISHERS, SHANNON, IR, vol. 36, no. 1, October 2004 (2004-10-01), pages 25 - 32, XP004603014, ISSN: 0923-1811 * |
WILSON N ET AL: "The role of BMP-2 and BMP-4 in follicle initiation and the murine hair cycle.", EXPERIMENTAL DERMATOLOGY. AUG 1999, vol. 8, no. 4, August 1999 (1999-08-01), pages 367 - 368, XP008066794, ISSN: 0906-6705 * |
Also Published As
Publication number | Publication date |
---|---|
CA2601436A1 (en) | 2006-10-05 |
MX2007011591A (en) | 2007-12-10 |
CN101309698A (en) | 2008-11-19 |
AU2006230434A1 (en) | 2006-10-05 |
US20060239951A1 (en) | 2006-10-26 |
WO2006105359A2 (en) | 2006-10-05 |
JP2008534607A (en) | 2008-08-28 |
BRPI0609504A2 (en) | 2010-04-13 |
EP1863518A2 (en) | 2007-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006105359A3 (en) | Methods for stimulating hair growth by administering bmps | |
WO2006138418A3 (en) | Improvement of cognitive performance with sirtuin activators | |
WO2001012199A3 (en) | Methoxyamine potentiation of temozolomide anti-cancer activity | |
WO2005123116A3 (en) | Compositions and methods for treating or preventing oxalate-related disease | |
WO2007140002A3 (en) | Method for treating non-hodgkin's lymphoma | |
WO2013142124A8 (en) | Solid forms of a thiophosphoramidate nucleotide prodrug | |
WO2006105527A3 (en) | Amylin and amylin agonists for treating psychiatric diseases and disorders | |
GB2463833A (en) | Methods and compositions for the treatment of neurological disorders | |
WO2005063232A8 (en) | Obesity and metabolic syndrome treatment with tanshinone derivatives which increase metabolic activity | |
WO2008067389A3 (en) | Modulation of sod protein synthesis for the treatment of neurodegenerative diseases | |
WO2006003388A3 (en) | Compositions and methods for treating inflammatory disorders | |
WO2007081710A3 (en) | Treatment modalities for autoimmune diseases | |
IL178390A0 (en) | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease | |
WO2005091853A3 (en) | Methods and compositions for treating il-13 related pathologies | |
TW200519110A (en) | Substituted tetrahydro-1H-pyrazolo [3, 4-c] pyridines, compositions comprising them, and use | |
WO2007146965A3 (en) | Compounds for the treatment of periodontal disease | |
WO2007058850A3 (en) | Inhibitors of akt activity | |
PL1761266T3 (en) | Compounds, formulations, and methods for treating or preventing inflammatory skin disorders | |
WO2008148074A3 (en) | Inhibitors of mtor and methods of treatment using same | |
WO2005118609A3 (en) | Small molecule stimulators of neuronal growth | |
WO2010004197A3 (en) | Pyridino-pyridinone derivatives, preparation thereof, and therapeutic use thereof | |
WO2007092496A3 (en) | 7,9-dihydro-purin-8-one and related analogs as hsp90-inhibitors | |
WO2010088450A3 (en) | Arylamide derivatives useful in the treatment of diseases associated with serca activity | |
WO2006113837A3 (en) | Inhibitors of akt activity | |
WO2006034035A3 (en) | Treatment of ischemia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680010142.X Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006740137 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2601436 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006230434 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2007/011591 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2008504403 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2006230434 Country of ref document: AU Date of ref document: 20060330 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 3968/KOLNP/2007 Country of ref document: IN |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
ENP | Entry into the national phase |
Ref document number: PI0609504 Country of ref document: BR Kind code of ref document: A2 |